Armata Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
ARMP$3.75-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| | | | | | |
|---|---|---|---|---|---|
| | Three Months Ended March 31, | ||||
| · 2026 · · 2025 | |||||
| Grant and award revenue | $789 | | $491 | ||
| Operating expenses | | | | | |
| Research and development | 6,111 | | | 5,429 | |
| General and administrative | 3,463 | | | 3,253 | |
| Total operating expenses | | 9,574 | | | 8,682 |
| Operating loss | (8,785) | | (8,191) | ||
| Other income (expense) | | | | ||
| Interest income | | 60 | | | 59 |
| Interest expense | | (5,559) | | | (3,602) |
| Change in fair value of the Convertible Loan | | (101,062) | | | 5,203 |
| Total other income (expense), net | (106,561) | | 1,660 | ||
| Net loss | $(115,346) | | $(6,531) | ||
| Per share information: | | | | | |
| Net loss per share, basic | $(3.16) | | $(0.18) | ||
| Weighted average shares outstanding, basic | | 36,530,284 | | | 36,184,802 |
| Net loss per share, diluted | $(3.16) | | $(0.20) | ||
| Weighted average shares outstanding, diluted | | 36,530,284 | | | 59,478,662 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.